Collectively, these results suggest that FFAR2 signaling functionally antagonizes lung cancer progression induced by TLR2 or TLR3 via the suppression of the AMPK-TAK1 signaling axis for the activation of NF-κB. Here, FFAR2 is linked to lung carcinoma.